BO-112 is under clinical development by Highlight Therapeutics and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BO-112’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BO-112 is under development for the treatment of aggressive solid tumors including metastasis from refractory non-small cell lung cancer, gastric cancer, gastroesophageal junction cancer, soft tissue sarcoma and hepatocellular carcinoma, renal cell carcinoma, leiomyosarcoma and squamous cell carcinoma of the head and neck. The drug candidate is administered through intratumoral route. The drug candidate targets retinoic acid inducible gene 1 protein (RIG 1), toll like receptor 3 (TLR 3) and melanoma differentiation associated protein 5 (MDA5). It was also under development for the treatment of melanoma, triple negative breast cancer, gastric cancer, gastroesophageal junction cancer, colorectal cancer and neuroendocrine tumors.
Highlight Therapeutics overview
Highlight Therapeutics is a clinical-stage immune-oncology company that conducts develops RNA-based therapies. The company’s pipeline product includes BO-112 that induces immunogenic cell death in solid tumors and simultaneously activates the immune system to certify optimal antigen processing and presentation to the adaptive immune system. Its BO-112 product is currently being investigated in clinical trials as a monotherapy and in combination with checkpoint inhibitors. Highlight Therapeutics’s services include formulation, preclinical development, manufacturing, and clinical trials. The company develops RNA-based therapies against validated and novel targets in cancer and immune cells. It operates in Madrid and Valencia, Spain. Highlight Therapeutics is headquartered in Paterna, Spain.
For a complete picture of BO-112’s drug-specific PTSR and LoA scores, buy the report here.